Stoke Therapeutics (STOK) Profit After Tax Growth (1y) (2019 - 2026)
Stoke Therapeutics (STOK) Profit After Tax Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Stoke Therapeutics | 1.86 Bn | 1.52 Bn | - | -144.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -144.28% |
| Dec 31, 2025 | -458.40% |
| Sep 30, 2025 | -43.76% |
| Jun 30, 2025 | 8.61% |
| Mar 31, 2025 | 528.17% |
| Dec 31, 2024 | 60.94% |
| Sep 30, 2024 | -8.72% |
| Jun 30, 2024 | 16.18% |
| Mar 31, 2024 | -16.98% |
| Dec 31, 2023 | -4.60% |
| Sep 30, 2023 | 6.90% |
| Jun 30, 2023 | -24.35% |
| Mar 31, 2023 | 8.54% |
| Dec 31, 2022 | -4.94% |
| Sep 30, 2022 | -15.55% |
| Jun 30, 2022 | -12.22% |
| Mar 31, 2022 | -46.78% |
| Dec 31, 2021 | -67.90% |
| Sep 30, 2021 | -65.13% |
| Jun 30, 2021 | -69.51% |